EVAXION_DEEPBLUE_RGB.png
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
October 09, 2024 08:00 ET | Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
EVAXION_DEEPBLUE_RGB.png
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
October 03, 2024 08:00 ET | Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
image1 (1).png
Evaxion significantly expands vaccine development collaboration with MSD
September 26, 2024 07:30 ET | Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
image1 (1).png
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
September 19, 2024 08:00 ET | Evaxion Biotech
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction featureThe launch will expectedly...
image1 (1).png
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
September 16, 2024 07:00 ET | Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
image1 (1).png
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
September 09, 2024 08:00 ET | Evaxion Biotech
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...
image1 (1).png
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET | Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
image1 (1).png
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
August 14, 2024 07:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
image1 (1).png
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
August 12, 2024 07:27 ET | Evaxion Biotech
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
image1 (1).png
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
August 08, 2024 08:00 ET | Evaxion Biotech
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is...